OPXA Share Price

Open 1.15 Change Price %
High 1.16 1 Day -0.10 -9.35
Low 0.96 1 Week 0.00 0.00
Close 0.97 1 Month 0.00 0.00
Volume 307280 1 Year -2.48 -71.88
52 Week High 3.55
52 Week Low 0.50
OPXA Important Levels
Resistance 2 1.16
Resistance 1 1.08
Pivot 1.03
Support 1 0.86
Support 2 0.78
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
RITT 0.04 33.33%
SCHS 0.04 33.33%
RPRX 0.56 27.27%
ATRM 1.73 27.21%
BSDM 0.62 26.53%
TISA 1.63 26.36%
SNTA 0.34 25.93%
OTT 2.39 25.13%
DGLY 2.65 20.45%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DRRX 0.78 -60.41%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

OPXA Technical Analysis 2
As on 20th Sep 2017 OPXA Share Price closed @ 0.97 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.92 & Buy for SHORT-TERM with Stoploss of 0.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
OPXA Target for October
1st Target up-side 1.14
2nd Target up-side 1.27
3rd Target up-side 1.39
1st Target down-side 0.8
2nd Target down-side 0.67
3rd Target down-side 0.55
OPXA Other Details
Segment EQ
Market Capital 14797129.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.opexatherapeutics.com
OPXA Address
OPXA
2635 Technology Forest Boulevard
The Woodlands, TX 77381
United States
Phone: 281-272-9331
Fax: 281-872-8585
OPXA Latest News
Interactive Technical Analysis Chart Opexa Therapeutics, Inc. ( OPXA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Opexa Therapeutics, Inc.
OPXA Business Profile
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.